Clinical presentation and outcome by age categories in XXXX : results from an international observational cohort.

@entity1 @entity712
AIMS: To assess, according to age groups, @entity1 ' characteristics according to region of origin, the chronic therapeutic management, prognostic utility of clinical variables, and natriuretic peptides. METHODS AND RESULTS: The GREAT registry consisted of @entity1 identified as presenting with @entity712 at the emergency department. Four groups of @entity1 were defined according to age: the young @entity1 group (<65   years); 'middle-old' (65-74   years), 'old-old' (75-84   years) and the 'oldest-old' (85-94   years). Follow-up at 1   year was performed via personal contact or national data registries at 1   year. Dataset consisted of 14   758 @entity1 aged up to 95   years, with the 'oldest-old' group being more prevalent in North America and Western Europe. The 30-day mortality rate were, respectively, 8.1%, 8.9%, 10.3%, and 16.3% among the four age groups and 1-year mortality rates were, respectively, 3.1%, 17.1%, 24.7%, and 39.9%. @entity712 treatment was less frequently administered with age (percentage of the 'fully treated' group was 14% in the 'young' compared with 2% in the 'oldest-old' @entity1 group). Reduced left ventricular ejection fraction was present in 70%, 62.3%, 52.5%, and 46.8% among the four age groups, respectively. The prognostic utility of most variables for short- and long-term outcome was attenuated with age, with the exception of natriuretic peptides. CONCLUSION: This study found a large heterogeneity in age among geographic regions and that the eldest are less likely to be treated in accordance with recommendations of current @entity712 guidelines. Natriuretic peptide concentrations retained prognostic value in @entity1 across age strata.
